Edoxaban
Ischemic and bleeding events after early initiation of direct oral anticoagulants for acute intracranial hemorrhage with non-valvular atrial fibrillation - A multicenter prospective registry.
This site is for U.S. Healthcare Professionals only.
Publications
This section includes selected Daiichi Sankyo-sponsored publications.
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
HER3-DXd
Other/Multi
The impact of HER3 dynamics altered by HER3-DXd alone and in combination with driver oncogene inhibitors on HER3-DXd efficacy
Komatsu N, Sato S, Nakamura R, et al.
Int J Mol Sci. 2026 Feb 17;27(4):1930. doi: 10.3390/ijms27041930.
Dato-DXd
Breast Cancer
Optimal dosage justification for datopotamab deruxtecan in HR-positive/HER2-negative breast cancer through model-informed drug development approaches
Tang Z, Lim K, Jiang Y, et al.
Clin Transl Sci. 2026 Feb;19(2):e70493. doi: 10.1111/cts.70493.
T-DXd
Lung Cancer
Trastuzumab deruxtecan in HER2-mutant metastatic non-small-cell lung cancer: A plain language summary of the DESTINY-Lung02 study
Jänne PA.
Future Oncol. 2026 Mar;22(6):659-670. doi: 10.1080/14796694.2025.2598216.
T-DXd
Breast Cancer
Comparative efficacy of trastuzumab deruxtecan versus guideline-recommended treatments for 2L+ unresectable locally advanced or metastatic HER2-mutant non-small cell lung cancer: A systematic review and indirect treatment comparison
Cappuzzo F, Zhang L, Dunton K, Dennis N, Le Nouveau P, Nevière A, Gauthier A.
Front Oncol. 2026 Feb 13;15:1708245. doi: 10.3389/fonc.2025.1708245.
Dato-DXd
Lung Cancer
TROPION-Lung10: A phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations
Newsom-Davis T, Melosky B, Heist RS, et al.
Front Oncol. 2026 Feb 11;16:1804953. doi: 10.3389/fonc.2026.1804953.
Quizartinib
Hematology
FLT3-ITD measurable residual disease from the QuANTUM-First trial
Levis MJ, Erba HP, Montesinos P, et al.
Blood Adv. 2026 Feb 10;10(3):917-928. doi: 10.1182/bloodadvances.2025016444.
Edoxaban
Cardiovascular - AF
Major bleeding risk assessment with atrial fibrillation post-TAVR: The HARHP score results from ENVISAGE-TAVI AF
Dangas GD, Unverdorben M, Hengstenberg C, et al.
JACC Cardiovasc Interv. 2026 Feb 9;19(3):359-368. doi: 10.1016/j.jcin.2025.11.028.
T-DXd
Breast Cancer
Real-world treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States
Modi S, Byng D, Zhang S, et al.
Breast. 2026 Apr;86:104721. doi: 10.1016/j.breast.2026.104721.
T-DXd
Breast Cancer
Safety and effectiveness of post-trastuzumab deruxtecan regimens in patients with HER2-positive metastatic breast cancer who discontinued trastuzumab deruxtecan due to interstitial lung disease
Tsurutani J, Nozawa K, Mukohara T, et al.
Breast. 2026 Apr;86:104722. doi: 10.1016/j.breast.2026.104722.
DataSource by Daiichi Sankyo website provides U.S.
healthcare professionals with high quality, fair balanced, evidence-based medical information.
The information provided is for education purposes only and is not intended as medical advice.
Please choose an option below